DCM
KNSA icon

Driehaus Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Driehaus Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9M Buy
718,199
+106,801
+17% +$5.54M 0.27% 128
2026
Q1 		$29.4M Sell
611,398
-21,429
-3% -$949K 0.22% 151
2025
Q4 		$26.1M Sell
632,827
-21,758
-3% -$873K 0.18% 170
2025
Q3 		$25.4M Buy
654,585
+6,605
+1% +$215K 0.18% 183
2025
Q2 		$17.9M Buy
647,980
+36,702
+6% +$934K 0.14% 193
2025
Q1 		$13.6M Sell
611,278
-2,272
-0.4% -$46.8K 0.13% 203
2024
Q4 		$12.1M Sell
613,550
-117,393
-16% -$2.68M 0.1% 225
2024
Q3 		$18.3M Buy
730,943
+115,107
+19% +$2.8M 0.16% 180
2024
Q2 		$11.5M Sell
615,836
-6,704
-1% -$126K 0.11% 201
2024
Q1 		$12.3M Sell
622,540
-39,175
-6% -$765K 0.12% 217
2023
Q4 		$11.6M Buy
661,715
+157,965
+31% +$2.6M 0.14% 217
2023
Q3 		$8.75M Buy
+503,750
New +$8.49M 0.11% 227

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Driehaus Capital Management's KNSA Position: Q2 2026 in Review

Driehaus Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 17% in Q2 2026, buying an estimated $5.54M and bringing the position to 718,199 shares worth $45.9M. The position accounts for 0.27% of the portfolio, ranked #128.

Driehaus Capital Management first reported a position in KNSA in Q3 2023 and has held it in 12 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Driehaus Capital Management held 718,199 shares of Kiniksa Pharmaceuticals worth $45.9M as of Q2 2026.
  • Driehaus Capital Management bought 106,801 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $5.54M.
  • Kiniksa Pharmaceuticals made up 0.27% of Driehaus Capital Management's portfolio in Q2 2026, its #128 holding.
  • Driehaus Capital Management first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.